Discover key truths about psoriasis, from symptoms and causes to effective management strategies to improve your quality of ...

If approved, ZORYVE cream would be the first and only topical PDE4 inhibitor indicated for plaque psoriasis in children as young as 2, offering patients and caregivers an important alternative to ...

The severe stress caused by family upheaval might tax a child's immune system in ways that increase their chances of autoimmune skin disease psoriasis.

Early childhood stress, especially before age 1, significantly increases psoriasis risk, with an odds ratio of 4.19. The study involved over 16,000 children, using data from the All Babies in ...

The US FDA has approved guselkumab for the treatment of moderate-to-severe plaque psoriasis and active psoriatic arthritis (PsA) in children aged 6 years or older who weigh at least 40 kg, according ...

TREMFYA® is now approved for pediatric patients living with moderate to severe plaque psoriasis, who are candidates for systemic therapy or phototherapy, and active psoriatic arthritis in children six ...

WESTLAKE VILLAGE, Calif., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in ...